secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2022-12-27T23:59:59+00:00
Accession:  0001140361-22-046943
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 2.01, 3.02, 5.02, 5.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Biosciences acquires F351 assets; GNI USA to own ~97.5% of combined company
--------------------------------------------------------------------------------

- Acquired F351 assets (Hydronidone, 15 ex-China patents expiring 2037) from GNI Group for $35M in stock (6.27M common + 12,340 Series X preferred).
- Business Combination Agreement: GNI USA contributes CPI and Further Challenger shares for ~954M Catalyst common shares; pre-close holders retain ~2.5% voting power.
- Combined company to own F351 assets and ~65% indirect controlling interest in Beijing Continent Pharmaceuticals.
- Board replaced: five directors resigned; new appointees include Ying Luo (CEO of GNI Japan), Thomas Eastling, Andrea Hunt, Nassim Usman, Augustine Lawlor.
- Special bonuses approved: CEO $861,750, interim CFO $277,763, CSO $429,187; additional payments contingent on ≥$10M distribution to stockholders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/0001140361-22-046943-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036122046943/brhc10045912_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-046943

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer